Actuate Therapeutics is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). We are developing elraglusib (formerly 9-ING-41), a small molecule that is des... Actuate Therapeutics is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). We are developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B. We believe that the blockade of GSK-3B signaling ultimately results in the death of the cancer cells and the regulation of anti-tumor immunity. We have exclusively licensed a portfolio of GSK-3 inhibitors developed in a collaboration between the University of Illinois-Chicago (UIC) and Northwestern University (NU). 詳細を表示
Actuate Corporation (NASDAQ: ACTU) (NASDAQ: BIRT), The people behind BIRT® and the leading open source Business Intelligence vendor, today announced that it has recognized...
Actuate Corporation (NASDAQ:BIRT), The people behind BIRT® and the leading open source Business Intelligence vendor, today reported that BIRT has now been downloaded over 10...
Actuate Corporation (NASDAQ: ACTU)(NASDAQ: BIRT), the people behind BIRT® and the leading open source Business Intelligence vendor, today announced financial results for the...
Actuate Corporation (NASDAQ:ACTU), The people behind BIRT® and the leader in open source Business Intelligence (BI), today announced that The Nasdaq Stock Market has approved...
Actuate Corporation (NASDAQ:ACTU), The people behind BIRT® and the leading open source Business Intelligence vendor, today announced the highlights of its upcoming Actuate...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 1.29 | 18.9149560117 | 6.82 | 8.93 | 6.27 | 73272 | 7.88347437 | CS |
4 | -0.04 | -0.490797546012 | 8.15 | 10 | 6.27 | 78063 | 7.96547591 | CS |
12 | 1.11 | 15.8571428571 | 7 | 10 | 6.27 | 58749 | 8.23205583 | CS |
26 | 3.11 | 62.2 | 5 | 10.162 | 5 | 39561 | 8.08947955 | CS |
52 | 3.11 | 62.2 | 5 | 10.162 | 5 | 19939 | 8.08947955 | CS |
156 | 3.11 | 62.2 | 5 | 10.162 | 5 | 6620 | 8.08947955 | CS |
260 | 3.11 | 62.2 | 5 | 10.162 | 5 | 4676 | 8.08947955 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約